OraQuick ADVANCE(R) to Be Centerpiece of Expanded HIV Testing in Philadelphia
07 Dicembre 2006 - 9:00PM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the leader in oral fluid
diagnostics, announced that its OraQuick ADVANCE� Rapid HIV 1/2
Antibody Test will be the centerpiece of a planned initiative in
the City of Philadelphia to provide oral fluid rapid HIV 1/2
testing to populations that are traditionally underserved and in
many instances unable to access routine medical care. The
initiative is being made possible through an initial $1.5 million
in increased funding to expand local HIV/AIDS testing and treatment
programs, the largest increase of its kind in the history of
Pennsylvania. The announcement was made today by State Sen. Vincent
Hughes (D-Phila.) and Dr. Calvin B. Johnson, Secretary of the
Pennsylvania Department of Health, at a press conference held in
Philadelphia at the Strawberry Mansion Health Center. �Knowing your
status is critical to curtailing the spread of this disease. By
expanding our use of state-of-the-art oral fluid rapid testing
products, we will be able to test more people and get them into
care sooner,� said Senator Hughes. "The Commonwealth and the City's
ongoing partnership with OraSure Technologies provides an ideal
opportunity for us to attack this devastating disease head on --
ensuring that the standards established for our HIV/AIDS prevention
and treatment efforts continue to be considered among the best in
the nation." The City of Philadelphia will be using the OraQuick
ADVANCE� HIV 1/2 test for this initiative and has committed to
purchase 16,500 tests by the end of 2006 in support of a
broad-scale campaign. �OraSure is thrilled to be working with the
City of Philadelphia and the Commonwealth of Pennsylvania on this
HIV testing campaign. This campaign illustrates the commitment of
individuals like Senator Hughes and Secretary Johnson who recognize
the importance of knowing your HIV status in order to help stem the
spread of the disease,� said OraSure President and Chief Executive
Officer, Douglas A. Michels speaking at the press conference. �Our
OraQuick ADVANCE� HIV 1/2 test is ideally suited for broad-scale
testing initiatives because of its simplicity, its high accuracy,
and very importantly, its oral fluid capability. We are extremely
pleased to be a partner in this effort.� In June 2006, Washington
D.C. announced a broad-scale campaign to test residents in the
district for HIV-1 and HIV-2 using OraQuick ADVANCE�.
Philadelphia�s campaign represents the second city-based HIV
testing initiative launched this year, and is expected to serve as
an additional model for large cities across the country in support
of the Centers for Disease Control and Prevention�s recently issued
recommendations for routine HIV testing in healthcare settings. The
OraQuick ADVANCE� Rapid HIV-1/2 Antibody Test, manufactured and
sold by OraSure Technologies, is the first and only U.S. Food and
Drug Administration ("FDA") approved and CLIA (Clinical Laboratory
Improvements Amendments Act of 1988) waived rapid point-of-care
test that can detect antibodies to both HIV-1 and HIV-2 in 20
minutes, using oral fluid, finger-stick or venipuncture whole blood
and plasma specimens. About OraSure Technologies OraSure
Technologies develops, manufactures and markets oral fluid specimen
collection devices using proprietary oral fluid technologies,
diagnostic products including immunoassays and other in vitro
diagnostic tests, and other medical devices. These products are
sold in the United States as well as internationally to various
clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. OraSure Technologies is the leading supplier
of oral-fluid collection devices and assays to the life insurance
industry and public health markets for the detection of HIV. In
addition, the Company supplies oral-fluid testing solutions for
drugs of abuse testing. For more information on the Company, please
go to http://www.orasure.com. Important Information This press
release contains certain forward-looking statements, including with
respect to product purchases and testing initiatives. Actual
results could be significantly different. Factors that could affect
results include the ability to market products; impact of
competitors, competing products and technology changes; ability to
develop, commercialize and market new products; market acceptance
of oral fluid testing or other products and changes in market
acceptance based on product performance; continued bulk purchases
by customers, including governmental agencies, and the ability to
fully deploy those purchases in a timely manner; ability to fund
research and development and other products and operations; ability
to obtain and maintain new or existing product distribution
channels; reliance on sole supply sources for critical product
components; availability of related products produced by third
parties; ability to obtain, and timing of obtaining, necessary
regulatory approvals; ability to comply with applicable regulatory
requirements; history of losses and ability to achieve sustained
profitability; volatility of our stock price; uncertainty relating
to patent protection and potential patent infringement claims;
uncertainty and costs of litigation relating to patents and other
intellectual property; availability of licenses to patents or other
technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally; loss or
impairment of sources of capital; ability to meet financial
covenants in agreements with financial institutions; ability to
retain qualified personnel; exposure to product liability, patent
infringement, and other types of litigation; changes in
international, federal or state laws and regulations; changes in
relationships with strategic partners and reliance on strategic
partners for the performance of critical activities under
collaborative arrangements; customer consolidations and inventory
practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil
unrest; ability to complete consolidation or restructuring
activities; ability to identify, complete and realize the full
benefits of potential acquisitions; and general political, business
and economic conditions. These and other factors are discussed more
fully in the Securities and Exchange Commission (�SEC�) filings of
OraSure Technologies, including its registration statements, its
Annual Report on Form 10-K for the year ended December 31, 2005,
its Quarterly Reports on Form 10-Q, and its other filings with the
SEC. Although forward-looking statements help to provide complete
information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. The
forward-looking statements are made as of the date of this press
release and OraSure Technologies undertakes no duty to update these
statements.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024